Cardeon AB reported improved operating results and a stronger equity ratio, despite a 15.7% decline in its listed portfolio and continued market headwinds. The company remains debt-free and is expanding its portfolio with a planned stake in AcroPharma.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.